Monitoring of Therapy or Recurrence in Breast Cancer with Cancer-specific Mutatio

描述(由申请人提供)：迫切需要个性化的方法来监测肿瘤状态和评估复发或治疗失败。常规监测手段包括临床体征、症状、实验室结果和昂贵的检查，如放射成像(CT扫描、骨扫描、PET扫描)。然而，更灵敏、更理想的定量方法将是有利的。我们寻求结合两种强大的分子技术来监测血液中的肿瘤，方法是识别和跟踪每个患者特有的“癌症突变标记”。四个核心观察是我们开发这种测试的目标的基础。(1)在最近的几项研究中，Vogelstein小组证明了100-200个体细胞突变通常发生在乳腺癌、结肠癌和其他癌症的外显子中。(2)大规模并行测序的最新技术进步允许在整个基因组(或其子集)上进行大量测序，并将允许在相对较短的时间内检测多个癌症相关基因中的体细胞肿瘤突变。(3)以前的研究表明，从坏死性或凋亡性癌细胞释放的癌症特异性DNA可以在血浆中检测到。(4)由该公司创始人开发的一种高度敏感和特殊的方法--焦磷酸分解-激活聚合(PAP)技术的技术进步，使在血液的血浆和细胞室中能够检测到含有这种癌症特异性特征的DNA的单一拷贝。这项拟议的研究将通过分析肿瘤和正常DNA，以及四名乳腺癌患者的系列血液样本，来制定“癌症突变特征”的操作标准。[这个项目的独特之处在于，我们将为每个患者识别一组肿瘤突变，这些突变(1)具体定义该患者的单个肿瘤，(2)不存在于患者匹配的正常组织中，提供真正个性化的“癌症特征”。]使用大规模平行测序，将在每个患者的肿瘤DNA中检测到约20个突变，经毛细管测序证实，正常DNA中没有突变。将为每个患者选择的五个突变中的每一个开发PAP分析。可靠的“癌症突变标记”的标准将被确定。考虑到混杂因素的可能性，假设每种癌症需要两到五个体细胞突变。有了“癌症突变标记”，血液样本将在诊断时和随后的临床过程中进行检测，以监测患者。结果将与标准的患者监测模式进行比较。这项第一阶段可行性研究的成功将导致第二阶段的临床研究，并最终实现癌症患者个性化个人测试的商业测试。 公共卫生相关性：对于癌症患者，更好的治疗或复发监测方法可以在降低成本的同时改善结果。传统的监测癌症进展的方法不够灵敏，无法确定治疗效果或及时检测肿瘤的复发。有了革命性的下一代测序的力量，识别个人独特的癌症突变特征成为可能(一种适用于所有癌症类型的方法)，在血液中可以检测到癌症特征的单分子。大规模平行测序和PAP(焦磷酸分解激活聚合)相结合对治疗或复发(运动)的监测有可能给癌症治疗带来革命性的变化。

DESCRIPTION (provided by applicant): Personalized methods are urgently needed for monitoring tumor status and assessing recurrence or treatment failure. Conventional means of monitoring include clinical signs, symptoms, laboratory results, and expensive tests such as radiographic imaging (CT scan, bone scan, PET scan). However, more sensitive and, ideally, more quantitative methods would be advantageous. We seek to combine two powerful molecular technologies to monitor tumors in blood by identifying and tracking, a "cancer mutation signature" specific for each individual patient. Four core observations underlie our goal of developing such a test. (1) In several recent studies, the Vogelstein group demonstrated that 100-200 somatic mutations generally occur in the exome of breast, colon, and other cancers. (2) Recent technological advances in massively parallel sequencing allow a vast amount of sequencing over an entire genome (or subset thereof) and would permit the detection of somatic tumor mutations in multiple cancer-related genes within a relatively short time. (3) Previous studies have shown that cancer-specific DNA released from necrotic or apoptotic cancer cells can be detected in plasma. (4) Technical advances in Pyrophosphorolysis-Activated Polymerization (PAP), a highly sensitive and specific method developed by the founder of this company, enables detection of a single copy of DNA harboring such cancer- specific signatures in both the plasma and cellular compartments of blood. The proposed study will develop operational criteria for a "cancer mutation signature" by analyzing tumor and normal DNA, as well as serial blood samples from four breast cancer patients. [What makes this project unique is the fact that we will identify a set of tumor mutations for each patient that (1) specifically defines the individual tumor of that patient and (2) are not present in the patient's matched normal tissue, providing a truly personalized "cancer signature".] Using massively parallel sequencing, about 20 mutations will be detected in the tumor DNA of each patient, confirmed by capillary sequencing, and shown to be absent in the normal DNA. PAP assays will be developed for each of five mutations chosen per patient. Criteria for a reliable "cancer mutation signature" will be determined. It is hypothesized that between two and five somatic mutations will be required per cancer, given the possibility of confounders. With the "cancer mutation signature", blood samples will be tested to monitor the patient at diagnosis and during the subsequent clinical course. Outcomes will be compared to the standard patient monitoring modalities. Success in this Phase I feasibility study will lead to a Phase II clinical study and eventually to a commercial test for individualized personal testing for cancer patients. PUBLIC HEALTH RELEVANCE: For patients with cancer, better methods for monitoring therapy or recurrence could improve outcome while reducing cost. Conventional means of monitoring cancer progression are not sensitive enough to determine the therapeutic effectiveness or to detect recurrence of the tumor in a timely manner. With the power of the revolutionary next-generation sequencing, it becomes possible to identify an individual's unique cancer mutation signature (a method applicable to all cancer types), in which single molecules of the cancer signature can be detected in blood. The monitoring of therapy or recurrence (MOTOR) with a combination of massively parallel sequencing and PAP (Pyrophosphorolysis-Activated Polymerization) has the potential to revolutionize cancer treatment.